Literature DB >> 12925008

Decrease of adenosine A1 receptor density and of adenosine neuromodulation in the hippocampus of kindled rats.

Nelson Rebola1, Joana E Coelho, Ana Rita Costenla, Luísa V Lopes, António Parada, Catarina R Oliveira, Patrício Soares-da-Silva, Alexandre de Mendonça, Rodrigo A Cunha.   

Abstract

Adenosine is a neuromodulator that has been proposed to be a major endogenous anticonvulsant acting via A1 receptors. We tested if implementation of kindling through stimulation of the amygdala affected A1 receptor-mediated neuromodulation in hippocampal slices taken from rats 4 weeks after the last stage 5 seizure. The A1 receptor agonist, N6-cyclopentyladenosine (CPA) (6-100 nm), inhibited field excitatory postsynaptic potential (fEPSP) slope with an EC50 of 19.1-19.5 nm in control and sham-operated rats, but was less potent in kindled rats (EC50 = 42.7 nm). This might result from a decreased number of A1 receptors in hippocampal nerve terminal membranes, because A1 receptor immunoreactivity decreased by 28 +/- 3% and the binding density of the A1 receptor agonist [3H]R-PIA decreased from 1702 +/- 64 to 962 +/- 78 fmol/mg protein in kindled compared with control rats. The tonic inhibition of hippocampal synaptic transmission by endogenous adenosine was also lower in kindled rats, because A1 receptor blockade with 50 nm 1,3-dipropyl-8-cyclopentyladenosine (DPCPX) enhanced fEPSP slope by 23 +/- 3% and theta-burst-induced long-term potentiation by 94 +/- 4% in control rats but was virtually devoid of effects in kindled rats. The evoked release of adenosine from hippocampal slices or nerve terminals was 56-71% lower in kindled rats probably due to the combined decrease in the capacity of adenosine transporters and decreased release of adenosine 5'-triphosphate (ATP), which was partially compensated by a higher extracellular catabolism of ATP into adenosine in kindled rats. These results indicate that, although adenosine might inhibit the onset of epileptogenesis, once kindling is installed, the efficiency of the adenosine inhibitory system is impaired.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12925008     DOI: 10.1046/j.1460-9568.2003.02815.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  44 in total

1.  Adenosine dysfunction and adenosine kinase in epileptogenesis.

Authors:  Detlev Boison
Journal:  Open Neurosci J       Date:  2010-01-01

2.  Enhanced ATP release and CD73-mediated adenosine formation sustain adenosine A2A receptor over-activation in a rat model of Parkinson's disease.

Authors:  Marta Carmo; Francisco Q Gonçalves; Paula M Canas; Jean-Pierre Oses; Francisco D Fernandes; Filipe V Duarte; Carlos M Palmeira; Angelo R Tomé; Paula Agostinho; Geanne M Andrade; Rodrigo A Cunha
Journal:  Br J Pharmacol       Date:  2019-08-01       Impact factor: 8.739

Review 3.  Adenosine augmentation therapies (AATs) for epilepsy: prospect of cell and gene therapies.

Authors:  Detlev Boison
Journal:  Epilepsy Res       Date:  2009-05-09       Impact factor: 3.045

4.  Cell and gene therapies for refractory epilepsy.

Authors:  Detlev Boison
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

Review 5.  Adverse and protective influences of adenosine on the newborn and embryo: implications for preterm white matter injury and embryo protection.

Authors:  Scott A Rivkees; Christopher C Wendler
Journal:  Pediatr Res       Date:  2011-04       Impact factor: 3.756

Review 6.  The role of adenosine in epilepsy.

Authors:  Landen Weltha; Jesica Reemmer; Detlev Boison
Journal:  Brain Res Bull       Date:  2018-11-20       Impact factor: 4.077

Review 7.  Comorbidities in Neurology: Is adenosine the common link?

Authors:  Detlev Boison; Eleonora Aronica
Journal:  Neuropharmacology       Date:  2015-05-13       Impact factor: 5.250

Review 8.  Glial adenosine kinase--a neuropathological marker of the epileptic brain.

Authors:  Eleonora Aronica; Ursula S Sandau; Anand Iyer; Detlev Boison
Journal:  Neurochem Int       Date:  2013-02-04       Impact factor: 3.921

9.  Lentiviral RNAi-induced downregulation of adenosine kinase in human mesenchymal stem cell grafts: a novel perspective for seizure control.

Authors:  Gaoying Ren; Tianfu Li; Jiang Quan Lan; Andrew Wilz; Roger P Simon; Detlev Boison
Journal:  Exp Neurol       Date:  2007-08-02       Impact factor: 5.330

10.  Release of adenosine and ATP during ischemia and epilepsy.

Authors:  Nicholas Dale; Bruno G Frenguelli
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.